BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Cherri S, Noventa S, Zaniboni A. Pancreatic adenocarcinoma: Beyond first line, where are we? World J Gastroenterol 2021; 27(17): 1847-1863 [PMID: 34007126 DOI: 10.3748/wjg.v27.i17.1847]
URL: https://www.wjgnet.com/1007-9327/full/v27/i17/1847.htm
Number Citing Articles
1
Sofía Aranxa Alonso Bracho, Octavio Jesús Arroyo Zavala, Jenner Laredo Gómez, José Roberto Vázquez Nieves. Metástasis cerebral múltiple de adenocarcinoma pancreático. Reporte de casoRevista de la Facultad de Medicina 2024; 67(5): 42 doi: 10.22201/fm.24484865e.2024.67.5.05
2
Alain Couvineau, Pascal Nicole, Valérie Gratio, Thierry Voisin. The Orexin receptors: Structural and anti-tumoral propertiesFrontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.931970
3
Anabela Barros, Catarina Pulido, Manuela Machado, Maria Brito, Nuno Couto, Olga Sousa, Sónia Melo, Hélder Mansinho. Treatment optimization of locally advanced and metastatic pancreatic cancer (Review)International Journal of Oncology 2021; 59(6) doi: 10.3892/ijo.2021.5290
4
Se-Il Go, Sang-Cheol Lee, Woo Kyun Bae, Dae Young Zang, Hyun Woo Lee, Joung Soon Jang, Jun Ho Ji, Jung Hoon Kim, Sanggon Park, Sun Jin Sym, Yaewon Yang, So Yeon Jeon, In Gyu Hwang, Sung Yong Oh, Jung Hun Kang. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3)European Journal of Cancer 2021; 157: 21 doi: 10.1016/j.ejca.2021.08.002
5
Giulia Orsi, Alessandro Cavaliere, Giampaolo Tortora, Sara Lonardi, Marina Macchini, Mariacristina Di Marco, Guido Giordano, Enrico Vasile, Mario Scartozzi, Silvia Bozzarelli, Silvia Noventa, Maria Grazia Rodriquenz, Anna Maria Militello, Ilario Giovanni Rapposelli, Ingrid Garajova, Stefania De Lorenzo, Barbara Merelli, Alessandro Bittoni, Lisa Salvatore, Letizia Procaccio, Chiara Paratore, Andrea Spallanzani, Umberto Peretti, Monica Niger, Elisa Giommoni, Ilaria Bernardini, Emiliano Tamburini, Katia Bernardino, Laura Forti, Maria Maddalena Valente, Stefano Cascinu, Michele Milella, Michele Reni. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)British Journal of Cancer 2023; 128(5): 877 doi: 10.1038/s41416-022-02086-w
6
Couvineau Alain, Nicole Pascal, Gratio Valérie, Voisin Thierry. Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging TargetMolecules 2021; 26(16): 4849 doi: 10.3390/molecules26164849
7
Özgen Ahmet YILDIRIM, Erkan ERDUR. Pancreatic cancer treatment after FOLFIRINOX: prognostic importance of chemotherapy dose intensity and albumin/globulin ratio in second lineJournal of Health Sciences and Medicine 2022; 5(1): 156 doi: 10.32322/jhsm.1011658
8
Norbert Marschner, Nina Haug, Susanna Hegewisch‐Becker, Marcel Reiser, Steffen Dörfel, Christian Lerchenmüller, Hartmut Linde, Thomas Wolf, Anna Hof, Anja Kaiser‐Osterhues, Karin Potthoff, Martina Jänicke. Head‐to‐head comparison of treatment sequences in advanced pancreatic cancer—Real‐world data from the prospective German TPK clinical cohort studyInternational Journal of Cancer 2024; 155(9): 1629 doi: 10.1002/ijc.35071